Founded in 2010, The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease reagents. Our portfolio of reagents continues to expand rapidly, and we are widely acknowledged to be a primary source of reagents and kits for the study of emerging diseases. In July of 2020, The Native Antigen Company was acquired by The LGC Group, a global leader in the life sciences sector, and is now part of the LGC Clinical Diagnostics business unit. Read more.
What do we do?
The Native Antigen Company develops and manufacturers premium quality antigens and antibodies as well as offering a range of services to the diagnostic and biopharmaceutical industries.
Our proprietary VirtuE™ expression system has been developed for the purpose of producing native-like proteins, which are widely adopted by leading in vitro diagnostic, vaccine and academic groups in cutting-edge R&D, where correct folding and glycosylation are vital. Our contract services range from antibody generation, to scale production of recombinant and native antigens, and bespoke assay development and QC.
Building on our recognised expertise in infectious diseases, we are expanding our portfolio to include a range of disease-state markers and other critical reagents for human health.
VirtuE Expression System
The Native Antigen Company has developed a proprietary HEK293 mammalian expression system (VirtuE) for expression of recombinant proteins. Our VirtuE system is able to introduce proper protein folding and full post-translational modifications, which are essential for full biological and antigenic activity. Read more.
The Native Antigen Company is a manufacturer of high quality antigens, antibodies and assays. We accept responsibility for the complete satisfaction of our customers. We exercise this responsibility through comprehensive training of our employees, adherence to established quality procedures, and total commitment to understanding and meeting customer needs. We will lead our business processes using meaningful metrics and dedication to continuously improve our products and performance. We will strive to continuously improve the development, cost and quality of our products, and continuously improve our customer service with regards to communication, complaint resolution and value for money. A bi-yearly management review of the entire Quality Management System is in place at The Native Antigen Company and is held to address issues and continuously improve the system.